Advances in treatment of chronic hepatitis C: 'pegylated' interferons.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11990646.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New regimens consisting of pegylated interferons plus ribavirin may produce a sustained virologic response in more than 50% of cases of chronic hepatitis C. In contrast, the combination of standard interferon alfa and ribavirin, which was the standard of care until recently, produced a sustained virologic response in 35% to 40% of cases. As the efficacy of newer regimens improves, additional steps to adequately manage their side effects and maximize adherence may become crucial.